-transparent.png){kind=logo}
The relation between estrogen receptors (ER) and/or progesterone receptors (PgR) and some clinical factors such as tumor size, axillary node involvement, histological tumor grade, and disease-free interval (DFI) in 500 patients with operable (TNM stage I-III) breast cancer was studied. ER-positive (ER+) tumors were commoner in older patients, whereas PgR-positive (PgR+) tumors were similarly distributed within the age groups. The concentration of ER+ protein also increased with age in contrast to PgR+ protein concentration. However, receptor status was not associated with menopausal status independently of age. Axillary node involvement influenced neither ER nor PgR status, but there was a statistically significant relation between tumor size and positivity of ER or PgR. There was no association between histologic tumor grade and either steroid receptor phenotype. DFI was longer in patients with ER+ than those with ER- tumors, independently of axillary nodal status. The positivity of PgR in patients with ER+ tumors contributed to an even longer DFI, suggesting that the combination of ER/PgR is a better indicator of DFI than ER or PgR alone.
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
January 1984,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
June 1983,
Cancer research,
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
January 2015,
Journal of clinical and diagnostic research : JCDR,
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
January 1983,
Breast cancer research and treatment,
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
May 1983,
Gan no rinsho. Japan journal of cancer clinics,
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
January 1983,
Revista espanola de oncologia,
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
November 1996,
International journal of oncology,
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
December 1998,
The Journal of steroid biochemistry and molecular biology,
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
May 2011,
Clinical advances in hematology & oncology : H&O,
B Brdar, and
D Graf, and
R Padovan, and
P Nola, and
N Rudan, and
Z Petrinec, and
B Sarcević, and
M Belicza
January 1981,
Acta obstetricia et gynecologica Scandinavica. Supplement,
